Sensorium Therapeutics Inc

Sensorium is a clinical-stage biotech company developing central nervous system (CNS) therapies derived from natural products and guided by artificial intelligence-powered drug discovery. The company's pipeline includes three programs—SENS-01 for social anxiety disorder (in Phase 1 trials), SENS-03 for drug-resistant epilepsy, and SENS-08 for cognitive dysfunction in neurodegenerative disease—identified through its SensAI platform, which analyzes patterns across natural product chemistry, tra...